Results 71 to 80 of about 745,289 (215)

Optimizing the enzymatic release of MMAE from isoDGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker

Frontiers in Pharmacology, 2023
Antibody-Drug Conjugates (ADCs) and Small Molecule-Drug Conjugates (SMDCs) represent successful examples of targeted drug-delivery technologies for overcoming unwanted side effects of conventional chemotherapy in cancer treatment.
Marco Zambra, Ivan Ranđelović, Francesco Talarico, Adina Borbély, Laura Svajda, Laura Svajda, József Tóvári, Gábor Mező, Gábor Mező, Lizeth Bodero, Sveva Colombo, Sveva Colombo, Federico Arrigoni, Elettra Fasola, Silvia Gazzola, Umberto Piarulli   +15 more
doaj   +1 more source

Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents

Pharmaceuticals
ADCs have emerged as a promising class of therapeutics, combining the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Although the majority of approved ADCs are still based on microtubule binder payloads,
Barbara Valsasina, Paolo Orsini, Chiara Terenghi, Alberto Ocana   +3 more
doaj   +1 more source

Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas

Hematology/Oncology and Stem Cell Therapy, 2023
Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy ...
Hamza Hashmi, Alicia Darwin, Taiga Nishihori   +2 more
doaj   +1 more source

pH-Degradable mannosylated nanogels for dendritic cell targeting [PDF]

, 2016
We report on the design of glycosylated nanogels via core-cross linking of amphiphilic non-water-soluble block copolymers composed of an acetylated glycosylated block and a pentafluorophenyl (PFP) activated ester block prepared by reversible addition ...
Ayres, Neil, De Coen, Ruben, De Geest, Bruno, De Koker, Stefaan, Grooten, Johan, Louage, Benoit, Lybaert, Lien, Nuhn, Lutz, Risseeuw, Martijn, Taylor, Leeanne, Udhayakumar, Vimal Kumar, Van Calenbergh, Serge, Vanparijs, Nane   +12 more
core   +2 more sources

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma

Frontiers in Pharmacology
Urothelial carcinoma (UC) is a common cancer characterized by high morbidity and mortality rates. Despite advancements in treatment, challenges such as recurrence and low response rates persist. Antibody-drug conjugates (ADCs) have emerged as a promising
Chia-Hsien Shih, Yu-Hua Lin, Yu-Hua Lin, Yu-Hua Lin, Hao-Lun Luo, Hao-Lun Luo, Wen-Wei Sung, Wen-Wei Sung, Wen-Wei Sung   +8 more
doaj   +1 more source

Novel antibody–drug conjugates for triple negative breast cancer

Therapeutic Advances in Medical Oncology, 2020
Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker,
Aiko Nagayama, Neelima Vidula, Leif Ellisen, Aditya Bardia   +3 more
doaj   +1 more source

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Frontiers in Oncology, 2022
Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a ...
Zu-Chian Chiang, Zu-Chian Chiang, Zu-Chian Chiang, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin, Jizhen Lin, Qi Chen   +11 more
doaj   +1 more source

Controlled drug delivery from composites of nanostructured porous silicon and poly(L-lactide) [PDF]

, 2012
Porous silicon (pSi) and poly(l-lactide) (PLLA) both display good biocompatibility and tunable degradation behavior, suggesting that composites of both materials are suitable candidates as biomaterials for localized drug delivery into the human body. The
Irani, Yazad, McInnes, Steven James, Voelcker, Nicolas Hans, Williams, Keryn Anne   +3 more
core   +1 more source

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. [PDF]

, 2020
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response.
Chari, Ajai, Mezzi, Khalid, Scott, Emma, Shah, Nina, Usmani, Saad Z   +4 more
core   +1 more source

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Pharmaceutics
Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on
Youngbo Choi, Youbeen Choi, Surin Hong
doaj   +1 more source